Colloidal gold-based immunochromatographic biosensor for quantitative detection of S100B in serum samples

Area of Science:

• Biochemistry
• Biomarkers
• Medical Diagnostics

Background:

• Traumatic brain injury (TBI) presents a significant public health challenge.
• Early and accurate diagnosis of TBI is crucial for patient outcomes.
• Identifying sensitive and specific biochemical markers for TBI is of high clinical importance.

Purpose of the Study:

• To develop a rapid, quantitative biosensor for the detection of S100B protein.
• To evaluate the sensitivity, specificity, and accuracy of the developed biosensor.
• To assess the clinical utility of the S100B biosensor for TBI management.

Main Methods:

• Development of a colloidal gold-labeled, double antibody sandwich immunochromatographic biosensor.
• Quantification of S100B protein using the developed biosensor.
• Assessment of cross-reactivity with other proteins (S100A, NSE, GFAP, PGP9.5).
• Determination of detection limit and linear range.
• Validation using clinical serum samples and comparison with chemiluminescence immunoassay.

Main Results:

• The biosensor rapidly quantified S100B protein within 15 minutes.
• High specificity was demonstrated with no cross-reactivity.
• The detection limit was 4.6 pg mL^-1 with a linear range of 0.01-2 ng mL^-1.
• The assay showed acceptable accuracy and correlated well with chemiluminescence immunoassay results in clinical samples.

Conclusions:

• The developed colloidal gold quantitative immunochromatographic biosensor is a rapid, sensitive, specific, and accurate tool for S100B detection.
• This biosensor holds significant clinical value for the early diagnosis of TBI.
• It can also aid in assessing disease progression and patient prognosis in TBI cases.